Compare Garmin Ltd. (GRMN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Zimmer Biomet Holdings Inc — how do they compare? Garmin Ltd. trades at $267.45 (market cap $51.77B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Garmin Ltd. is far larger — about 3.1× Zimmer Biomet Holdings Inc's market cap, and Garmin Ltd. pays the higher dividend (1.56%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| GRMN | ZBH | |
|---|---|---|
Market Cap | $51.77B | $16.95B |
Volume | 961,398 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $313.16 | $103.98 |
52-Week Low | $187.10 | $79.58 |
Typical Hold Time | 83 Days | 89 Days |
Enterprise Value | $49.28B | $24.02B |
Dividend Yield | 1.56% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.36, down 2.82% on the day, reflecting a recent bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.81 surpassing the $2.30 expectation. Revenue and net income have shown steady growth, reaching $7.25 billion and $1.66 billion respectively in 2025. Positive news includes product awards and new feature rollouts, yet analyst consensus remains heavily weighted toward Hold.
The outlook balances robust profitability and growth against a cautious Wall Street sentiment and near-term technical weakness. Investment opportunity lies in the company's strong execution and product innovation, but risks include competitive pressures and market volatility. The consensus price target of $320.25 suggests significant potential upside from the current price if positive earnings trends continue.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
